REGENXBIO Inc (RGNX) Actualités

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 PR Newswire ROCKVILLE...

Form 8-K - Current report

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111...

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PR Newswire NORTH CHICAGO, Ill. and...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire NEW YORK...

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE®...

Form 8-K - Current report

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates PR Newswire ROCKVILLE...